Company intelligence / Profile preview

Myopharm

Melbourne, Victoria, Australiamyopharm.com ↗

Ownership: Private
Development stage: Other

Overview

Myopharm is a clinical-stage Australian biopharmaceutical company developing targeted therapies and consumer health products for chronic metabolic and inflammatory diseases. Its lead candidate, TriGlytza®, targets pro-inflammatory pathways in Type 2 diabetes and has US FDA IND approval covering up to 68 metabolic diseases. The company also markets clinically validated FSMPs generating positive cash flow, with multiple out-license agreements executed in 2023. Clinical trials have been conducted at leading Australian research institutes.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Small moleculeFood for Special Medical Purpose (FSMP) products
Industry: Biotech

Drug pipeline

3 assets

TriGlytza

2 more assets in the full pipeline.

Request access →

Partnerships

Multiple out-license agreements executed in 2023.Academic partnerships with Adelaide University and Baker IDI Heart & Diabetes Institute supporting R&D.

Beyond the preview

Go deeper on Myopharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myopharm.

Explore the full profile